GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia

J Clin Endocrinol Metab. 2020 Aug 1;105(8):e3000-e3002. doi: 10.1210/clinem/dgaa314.

Authors

Maria J Redondo¹, Fida Bacha^{1

2}

Affiliations

¹ Diabetes and Endocrinology Section, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
² Children's Nutrition Research Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.

No abstract available

Keywords: GLP-1 receptor agonists; albiglutide; c-peptide; clinical trial; type 1 diabetes; youth.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Adult
Blood Glucose
Diabetes Mellitus, Type 1* / drug therapy
Glucagon-Like Peptide 1 / analogs & derivatives
Glucagon-Like Peptide-1 Receptor
Humans

Substances

Blood Glucose
Glucagon-Like Peptide-1 Receptor
rGLP-1 protein
Glucagon-Like Peptide 1